Abstract Library

#3310 Ectopic Cushing’s syndrome: Experience from a tertiary care center

Introduction: Neuroendocrine neoplasms (NENs) causing ectopic Cushing’s syndrome (ECS) are relatively rare and very challenging to treat.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lase I

Authors: Lase I, Grönberg M, Strele I, Kozlovacki G, Norlën O,

Keywords: Ectopic Cushing’s syndrome, ACTH, neuroendocrine, hypercortisolism, multiple hormone secretion, bilateral adrenalectomy,

#1708 STREET - Somatostatin Treatment Experience Trial

Introduction: Somatostatin analogs (SSA) delay progress and decrease symptoms in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). It is not known whether patients’ experiences of injection treatment differ between different SSAs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Almquist M, Myrenfors P, Ström T, Kozlovacki G,

Keywords: somatostatin analogs, octreotide, lanreotide, quality of life, injection,

#1337 O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors

Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Polozkova S, Stepanova E, Delektorskaya V, Kozlov N, Gorbunova V,

Keywords: aranoza, MGMT, chemotherapy, NETs,

#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP

Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kozlovacki G, Welin S, Eriksson B, Granberg D, Gaasvik-Blomqvist L,

Keywords: pasireotide, octreotide LAR, small intestinal NET, diarrhea, VIP ,

#437 mTOR Expression in Primary Pancreatic Neuroendocrine Tumors and their Metastases

Introduction: The mammalian target of rapamycin (mTOR), an important regulator of cell proliferation and invasion, is activated in pancreatic neuroendocrine tumors (PNETs). Information on detailed expression of mTOR in locally advanced or metastatic PNET is poorly described.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kozlov N, Pavlovskaya A,

Keywords: neuroendocrine, pancreatic, tumor, metastases, p-mTOR, immunohistochemistry,